Pharmaceutical

Bharat Biotech acquires licence for GSK’s Shigella vaccine development

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and distribution.

Jun 15, 2025 - 06:00
Bharat Biotech acquires licence for GSK’s Shigella vaccine development
GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for the continued development and distribution.
Read the original article

Tags:

Previous Article

Myasthenia gravis market to reach $10.3bn across 7MM by 2034

Next Article

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: UnitedHealth starts bidding war with $3.3 billion offer for Amedisys

STAT+: UnitedHealth starts bidding war with $3.3 billio...

Jun 6, 2023

Harnessing the untapped potential of medicines access 

Harnessing the untapped potential of medicines access 

Jan 25, 2024

Coherus divests Udenyca franchise to Intas for up to $558.4m

Coherus divests Udenyca franchise to Intas for up to $5...

Apr 16, 2025